BEAM THERAPEUTICS INC (BEAM:NASDAQ)
$29.03 -0.38 (-1.2921%)
Analysed BEAM THERAPEUTICS INC (BEAM:NASDAQ) News Sources
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
13-05-2026
yahoo.com
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?
18-05-2026
fool.com
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
18-05-2026
yahoo.com
Beam Therapeutics Data Puts BEAM 302 And AAT Disease In Focus
19-05-2026
yahoo.com
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
19-05-2026
yahoo.com
Two Programs That Could Make or Break Beam Therapeutics Inc (BEAM) Stock
20-05-2026
yahoo.com
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances
20-05-2026
marketbeat.com
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?
26-05-2026
fool.com
Beam Therapeutics (BEAM) Is Up 17.6% After Advancing BEAM-302 Toward Accelerated Approval in AATD
28-05-2026
yahoo.com
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
02-06-2026
yahoo.com
What is the current price of BEAM THERAPEUTICS INC (BEAM:NASDAQ)?
The current price of BEAM THERAPEUTICS INC (BEAM:NASDAQ) is $29.03.
BEAM THERAPEUTICS INC (BEAM:NASDAQ) absolute price change since previous trading day?
The absolute price change of BEAM THERAPEUTICS INC (BEAM:NASDAQ) since the previous trading day is $-0.38.
BEAM THERAPEUTICS INC (BEAM:NASDAQ) percentage price change since previous trading day?
The percentage price change of BEAM THERAPEUTICS INC (BEAM:NASDAQ) since the previous trading day is -1.2921%.
What is the most recent average sentiment score for BEAM THERAPEUTICS INC (BEAM:NASDAQ)?
The most recent average sentiment score for BEAM THERAPEUTICS INC (BEAM:NASDAQ) is 88 out of 100.
What is the most recent average sentiment for BEAM THERAPEUTICS INC (BEAM:NASDAQ)?
The most recent sentiment for BEAM THERAPEUTICS INC (BEAM:NASDAQ) is .
SEC-8K** Filing Available For BEAM THERAPEUTICS INC (BEAM:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.